Utah’s Life Sciences Companies
-
Attostat is now EVŌQ Nano – Seeks Next Round of Investment Following Antimicrobial Efficacy Studies
Attostat is now EVŌQ Nano! The Utah start-up has a new name, a clean look and a fresh…
-
Novel Embolic Device Used for Arterial and Venous Tumor Treatments
Fluidx Medical Technology has announced successful patient use of the GPX Embolic Device to therapeutically devascularize, or block…
-
MAYOR ERIN MENDENHALL’S SALT LAKE CITY 2021 PLAN INCLUDES BIOHIVE
Last week, Salt Lake City (SLC) Mayor Erin Mendenhall gave her second State of the City address –…
-
Spectrum Solutions Collaborates with UCLA on Saliva-Based Next-Gen Sequencing (NGS) Liquid Biopsy Research for the Early Detection of Lung Cancer
Spectrum Solutions, LLC on January 27 announced it is sponsoring research in collaboration with the UCLA School of…
-
Control Medical Technology Announces New Device Removes Large Blood Clots in 1st Deep Vein Thrombosis (DVT) Patient Use
Control Medical Technology today announced the FDA cleared Control 11F Mechanical Thrombectomy system was used to remove large…
-
SDP Oncology Announces First Patient Dosed in Phase 1/2 Study of TP-0184 for the Treatment of Anemia in Patients with Low or Intermediate Risk Myelodysplastic Syndromes
Lehi-based Sumitomo Dainippon Pharma Oncology (SDP Oncology) recently announced that the first patient has been dosed in…
-
Co-Diagnostics Anticipates Reporting Highest Quarterly Revenue Following Demand for COVID-19 Diagnostic Products
Based on its preliminary internal financial reporting for the fourth quarter 2020, Co-Diagnostics has announced that unaudited quarterly…
-
Clene Nanomedicine Closes Merger with Tottenham Acquisition I Limited; Provides Corporate Update
Clene Nanomedicine, Inc. (Clene) last week announced the closing of a merger with Tottenham Acquisition I Limited (“Tottenham”)…
-
Early Risk Identification at Core of Innovative Kidney Care Partnership Between Renalytix, DaVita
Kidney care innovators Renalytix AI and DaVita are partnering on a new program aimed at slowing disease progression…
-
Co-Diagnostics Designs Test to Detect Mutations for New Coronavirus Strain Using CoPrimer™ Platform
Co-Diagnostics has announced that it has completed principal design work for a PCR test that would allow researchers…
-
Vertex Announces FDA Approvals for Expanded Use of Cystic Fibrosis Medicines
Vertex has announced FDA approval of eligibility for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include people with cystic fibrosis (CF)…
-
Phoenix PharmaLabs Announces New Investment Offering with Netcapital
Phoenix PharmaLabs (Phoenix), a Utah company developing potent, non-addictive treatments for pain and opioid and cocaine addictions, announced…
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- chair
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
